Established and Emerging Less Invasive Biomarkers and Technologies for Lung Cancer Screening: Puerto Rican Context
Onco · 01.04.2026 · 6 (2) · 18
DOI: 10.3390/onco6020018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Onco, online erschienen am 01.04.2026. Verfasst von Keisy Rodriguez-Villafañe und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Sciences Department, School of Pharmacy, University of Puerto Rico, Medical Sciences Campus, San Juan, PR 00936, USA. Die Arbeit nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NCI NIH HHS, NIMHD NIH HHS.
Abstract (Originalsprache)
Background/Objectives: In Puerto Rico (PR), lung cancer mortality remains high because diagnoses frequently occur at advanced stages. Although low-dose computed tomography (LDCT) lowers lung cancer–specific mortality, this screening is difficult to operationalize locally due to high false-positive rates, radiology capacity constraints, payer limitations, and geographic barriers affecting rural populations.
Methods
We performed a narrative review on the literature from 2001–2026 of established and emerging detection strategies—LDCT; serum biomarkers (CEA, CYFRA-21-1, NSE, ProGRP, SCC-Ag, HE4, Hp, TAAb); breath analysis (FeNO and VOCs); and liquid biopsy (ctDNAs/CTCs/miRNAs). We assessed technical performance, feasibility, and health-system fit in PR and then synthesized these findings into an implementable biomarker-first triage workflow for are.
Results
Multiplex serum panels analyzed with machine learning outperform single markers and TAAb provide high specificity with biological lead time, supporting their use as a triage gateway before LDCT. Breathomics is also feasible at the point of care. Liquid biopsy has modest sensitivity in very-early disease yet provides molecular adjudication for indeterminate nodules. A stepwise pathway—expanded risk assessment, integrated multi-panel testing in primary care, LDCT reserved for biomarker-positive individuals, and liquid biopsy when imaging is inconclusive—can enrich pre-test probability, reduce unnecessary scans, align with capitation, and protect limited radiology capacity.
Conclusions
An integrated, non-invasive, biomarker-first triage model offers a pragmatic, equitable route to earlier lung cancer detection in PR and resource stewardship, while reducing disparities.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pharmaceutical Sciences Department, School of Pharmacy, University of Puerto Rico, Medical Sciences Campus, San Juan, PR 00936, USA.
- School of Naturopathic Medicine, Universidad Ana G. Mendez Gurabo Campus, Gurabo, PR 00778, USA.
- Biology Department, University of Puerto Rico, Cayey Campus, Cayey, PR 00736, USA.
- Biochemistry & Pharmacology Department, San Juan Bautista School of Medicine, Caguas, PR 00726, USA.
ORCID-Profile: Yamixa Delgado
Förderung
- NIGMS NIH HHS
- NCI NIH HHS
- NIMHD NIH HHS
- Puerto Rico IDeA Network Biomedical Research Excellence
- Hispanic Clinical and Translational Research Education and Career Development (HCTRECD) Program
- COBRE Puerto Rico Center for Microbiome Science
- Cancer Prevention and Control (CAPAC) Research Training Program
Zitieren
APA
Rodriguez-Villafañe, K., Santiago, C., Figueroa, J. E., Figueroa, E., & Delgado, Y. (2026). Established and Emerging Less Invasive Biomarkers and Technologies for Lung Cancer Screening: Puerto Rican Context. Onco, 6(2), 18. https://doi.org/10.3390/onco6020018
Vancouver
Rodriguez-Villafañe K, Santiago C, Figueroa JE, Figueroa E, Delgado Y. Established and Emerging Less Invasive Biomarkers and Technologies for Lung Cancer Screening: Puerto Rican Context. Onco. 2026;6(2):18. doi:10.3390/onco6020018
BibTeX
@article{RodriguezVillafae2026,
author = {Rodriguez-Villafañe, Keisy and Santiago, Clara and Figueroa, Juan E and Figueroa, Edwin and Delgado, Yamixa},
title = {Established and Emerging Less Invasive Biomarkers and Technologies for Lung Cancer Screening: Puerto Rican Context},
journal = {Onco},
year = {2026},
volume = {6},
number = {2},
pages = {18},
doi = {10.3390/onco6020018}
}
EUVIMED